Alder Therapeutics reports positive results in Phase IIb study of ALD 403 to treat and prevent migraine.
Alder BioPharmaceuticals, Inc.announced positive top-line data from two clinical trials evaluating ALD 403, Alder’s proprietary monoclonal antibody product candidate for migraine prevention that targets calcitonin gene-related peptide (CGRP). Positive top-line data from a Phase IIb study of patients with chronic migraine demonstrated that ALD 403 acted rapidly and prevented migraine over the entire 12 week study period, meeting both primary and secondary efficacy endpoints. Additionally, positive Phase 1 study data demonstrated that the pharmacokinetics and pharmacodynamics by intravenous (IV), subcutaneous (SC) or intramuscular (IM) injection of ALD 403 support a quarterly single injection dosing strategy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.